Latest Financial Results
Q2 2023
Quarter Ended Jun 30, 2023
$348.2M
Total revenue of $348.2 million, up 29% from $269.7 million for the prior-year quarter$13.2M
Net income attributable to ApolloMed of $13.2 million, up 10% from $12.0 million for the prior-year quarter$35.8M
Adjusted EBITDA of $35.8 million, up 44% from $24.9 million for the prior-year quarterFor complete information regarding our financials, see our periodic filings